Role of PET in lymphoma

Chang Gung Medical Journal

Volumn 28, Issue 5, 2005, Pages 315-325

  Schwaiger, Markus ^a,b   Wieder, Hinrich ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Fluoro 2 deoxy D glucose (FDG); Lymphoma; Positron emission tomography (PET)

Indexed keywords

FLUORODEOXYGLUCOSE F 18; GALLIUM CITRATE GA 67; TRACER;

BONE MARROW; CANCER DIAGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CANCER THERAPY; CHEMOSENSITIVITY; COMPUTER ASSISTED TOMOGRAPHY; CYTOTOXICITY; DIAGNOSTIC IMAGING; HODGKIN DISEASE; HUMAN; INCIDENCE; INTERMETHOD COMPARISON; LABORATORY DIAGNOSIS; NONHODGKIN LYMPHOMA; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; REVIEW;

AMINO ACIDS; BONE MARROW; CELL PROLIFERATION; FLUORODEOXYGLUCOSE F18; GALLIUM RADIOISOTOPES; HUMANS; LYMPHOMA; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 22544437583     PISSN: 02558270     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (33)

1. Elstrom R, Guan L, Baker G, et al. Utility of FDG-PET scanning in lymphoma by WHO classification. Blood 2003;101:3875-6.
2. Buchmann I, Reske SN. Novel imaging techniques in NHL: clinical results with PET imaging. Ann Hematol 2001;80(Suppl 3):B54-7.
3. Weihrauch MR, Re D, Bischoff S, Dietlein M, et al. Whole-body positron emission tomography using 18 fluorodeoxyglucose for initial staging of patients with Hodgkin's disease. Ann Hematol 2002;81:20-5.
4. Wirth A, Seymour JF, Hicks RJ, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography, gallium-67 scintigraphy, and conventional staging for Hodgkin's disease and non-Hodgkin's lymphoma. Am J Med 2002;112:262-8.
5. Sasiki M, Kuwabara Y, Koga H, et al. Clinical impact of whole body FDG-PET on the staging and therapeutic decision making for malignant lymphoma; Ann Nucl Med 2002;16:337-45.
6. Foo SS, Mitchell PL, Berlangieri SU, et al. Positron emission tomography scanning in the assessment of patients with lymphoma. Intern Med J 2004;34:388-97.
7. Schaefer NG, Hany TF, Taverna C, et al. Non-Hodgkin lymphoma and Hodgkin disease: coregistered FDG PET and CT at staging and restaging - do we need contrast-enhanced CT? Radiology 2004;232:823-9.
8. 18F]-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) for accurate staging of Hodgkin's disease. Ann Oncol 1998;9:1117-22.
9. Buchmann I, Moog F, Schirrmeister H, Reske SN. Positron emission tomography for detection and staging of malignant lymphoma. Recent Results Cancer Res 2000;156:78-89.
10. Jerusalem G, Hustinx R, Beguin Y, Fillet G. The value of positron emission tomography (PET) imaging in disease staging and therapy assessment. Ann Oncol 2002;13(Suppl 4):227-34.
11. Naumann R, Beuthien-Baumann B. Positron emission tomography in the management of patients with indolent non-Hodgkin's lymphoma. Clin Lymphoma 2003;4:50-1.
12. Najjar F, Hustinx R, Jerusalem G, et al. Positron emission tomography (PET) for staging low-grade non-Hodgkin's lymphomas (NHL). Cancer Biother Radiopharm 2001;16:297-304.
13. Burton C, Ell P, Linch D. The role of PET imaging in lymphoma. Br J Haematol 2004;126:772-84.
14. Freudenberg LS, Antoch G, Schutt P, et al. FDG-PET/CT in re-staging of patients with lymphoma. Eur J Nucl Med Mol Imaging 2004;31:325-9.
15. 18F]FDG-PET a valid alternative to conventional diagnostic methods? J Clin Oncol 2001;19:414-9.
16. 18F-FDG PET for the evaluation of patients with Hodgkin's disease and non-Hodgkin's lymphoma. Nucl Med Commun 1999;20:13-20.
17. Zinzani PL, Magagnoli M, Chierichetti F, et al. The role of positron emission tomography (PET) in the management of lymphoma patients. Ann Oncol 1999;10:1181-4.
18. Mikhaeel NG, Timothy AR, Hain SF, O'Doherty MJ. 18-FDG-PET for the assessment of residual masses on CT following treatment of lymphomas. Ann Oncol 2000; 11(Suppl 1): 147-50.
19. Juweid ME. Radioimmunotherapy of B-cell non-Hodgkin's lymphoma: from clinical trials to clinical practice. J Nucl Med 2002;43:1507-29.
20. 18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease. Blood 2001;98:2930-4.
21. Mikhaeel NG, Mainwaring P, Nunan T, et al. Prognostic value of interim and post treatment FDG-PET scanning in Hodgkin lymphoma (abstract). Ann Oncol 2002; 13 (Suppl 2):21.
22. Zinzani PL, Fanti S, Battista G, et al. Predictive role of positron emission tomography (PET) in the outcome of lymphoma patients. Br J Cancer 2004;91:850-4.
23. Romer W, Hanauske AR, Ziegler S, et al. Positron emission tomography in non-Hodgkin's lymphoma: assessment of chemotherapy with fluorodeoxyglucose. Blood 1998;91:4464-71.
24. 18F-FDG uptake after a few cycles of polychemotherapy is predictive of treatment failure in non-Hodgkin's lymphoma. Haematologica 2000;85:613-8.
25. 18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma. Ann Oncol 2002;13:1356-63.
26. Kostakoglu L, Leonard JP, Kuji I, et al. Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and Ga-67 scintigraphy in evaluation of lymphoma. Cancer 2002;94:879-88.
27. Filmot JE, Czernin J, Yap C. Value of F-18 fluorodeoxyglucose positron emission tomography for predicting the clinical outcome of patients with aggressive lymphoma prior to and after autologous stem-cell transplantation. Chest 2003;124:608-13
28. Cremerius U, Fabry U, Wildberger JE, et al. Pre-transplant positron emission tomography (PET) using fluorine-18-fluoro-deoxyglucose (FDG) predicts outcome in patients treated with high-dose chemotherapy and autologous stem cell transplantation for non-Hodgkin's lymphoma. Bone Marrow Transplant 2002;30:103-11.
29. 18F] 2-fluoro-D-2-deoxyglucose (FDG-PET) predicts relapse of malignant lymphoma after high-dose therapy with stem cell transplantation. Leukemia 2002;16:260-7.
30. (18)F] FDG for therapy response monitoring in lymphoma patients. Eur J Nucl Med Mol Imaging 2003;30(Suppl 1):S97-105.
31. Scheidhauer K, Walter C, Seemann MD. FDG PET and other imaging modalities in the primary diagnosis of suspicious breast lesions. Eur J Nucl Med Mol Imaging 2004;31(Suppl 1):S70-9.
32. Burton C, Ell P, Linch D. The role of PET imaging in lymphoma. Br J Haematol 2004;126:772-84.
33. 18F-FDG. J Nucl Med 2003;44:533-9.